Background Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) in Japan. The clinical course and factors related to the progression of DKD to ESRD are important issues when treating patients with DKD. Methods Ninety-one type 2 diabetic patients with DKD that had progressed from chronic kidney disease (CKD) stages G1-3 on their initial clinical visit to ESRD were enrolled. The decline in the estimated glomerular filtration rate (eGFR) was analyzed and the initial clinical factors that influenced the decline rate were explored. Results There was a linear decline in eGFR before progression to ESRD, with a median annual decline rate (DeGFR) of 9.2 mL/min/1.73 m 2 . In all patients, a history of coronary artery disease and increased levels of initial eGFR and high-density lipoprotein cholesterol (HDL-C) were positive predictors of log DeGFR, whereas age, history of cerebral infarction (CI), and an increased level of serum albumin were negative predictors of log DeGFR. In patients with CKD stages G1-2 on their first visit, male sex and increased diastolic blood pressure were positive predictors. In patients with CKD stage G3 on their first visit, an increased level of LDL-C was a positive predictor, whereas a history of CI and an increased level of serum total bilirubin (TBil) were negative predictors. Conclusion In addition to the common risk factors, initial eGFR, HDL-C, and TBil were identified as novel risk factors for ESRD. These risk factors may differ between patients with early and advanced stages of CKD.
Introduction
In Japan, diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) [1] . Once overt nephropathy occurs without specific intervention in typical diabetic nephropathy, the glomerular filtration rate (GFR) gradually decreases at a highly variable rate within several years [2] .
A number of studies on estimated GFR (eGFR) decline rates in patients with type 1 diabetes have been reported [3] [4] [5] . eGFR trajectories until ESRD and the distribution of eGFR slopes were demonstrated in a study of 240 patients with proteinuria [4] . However, little is known about eGFR trajectories in patients with type 2 diabetes who are unresponsive to treatment and have reached ESRD. Analyzing these eGFR trajectories and eGFR decline rates in patients with type 2 diabetes is useful for evaluating the interval from overt nephropathy to ESRD. It is still unclear whether common risk factors for progression to DKD [6, 7] , such as albuminuria and blood pressure (BP), could be predictors of eGFR decline rate.
We retrospectively analyzed the eGFR trajectories of 91 Japanese patients with DKD due to type 2 diabetes from the first clinical visit until ESRD was reached. We also searched for factors influencing eGFR decline rates on the first visit.
Methods

Study population
A total of 167 outpatients with type 2 diabetes who first visited the Chiba Central Medical Center (CCMC) from 1999 to 2013 and developed ESRD between 2003 and 2015 were enrolled. ESRD was defined as eGFR of \15 mL/ min/1.73 m 2 . The KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease (CKD) were used to classify CKD based on etiology, GFR, and category of albuminuria [6] . Patients with CKD stages G4-5 on their initial visit and those with any clinical or laboratory evidence of other kidney or urinary tract diseases were excluded.
After applying the exclusion criteria, 91 type 2 diabetic patients with DKD were included. DKD was diagnosed according to one of the following criteria: (1) presence of diabetic retinopathy (DR) and albuminuria on the first visit and (2) onset of DR followed by albuminuria (normo-or microalbuminuria) during follow-up [8] . At the time of data analysis, hemodialysis was initiated in 77 patients, and 2 patients died because of uremia.
This study was approved by the ethics review board of CCMC and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Study design
Every 1-2 months, physical examination and laboratory data, including glycated hemoglobin (HbA1c) level, eGFR, and albumin-to-creatinine ratio (ACR), were retrospectively collected from the clinical records. HbA1c level was measured using high-performance liquid chromatography. Other variables, including body mass index (BMI), BP, low-density lipoprotein cholesterol (LDL-C) level, highdensity lipoprotein cholesterol (HDL-C) level, serum creatinine level, ACR, and other biochemical marker levels, were determined by standard methods.
eGFR was calculated using the following equation proposed by the Japanese Society of Nephrology: eGFR (mL/min/1.73 m 2 ) = 194 9 [age (years)] -0.287 9 serum creatinine (mg/dL)] -1.094 (90.739, if female) [9] . For each patient, a multivariate linear regression analysis model of time versus eGFR (least squares method) was created; the slope of the regression line during CKD stages G3-4 was used to estimate the eGFR slope (DeGFR) in all patients.
To minimize the effects of eGFR fluctuation, all eGFR values in CKD stages G3-4 were used in the multivariate linear regression analysis. The DeGFR was expressed as mL/1.73 m 2 per year. DR was assessed by ophthalmologists who examined the retina on the first visit and during the follow-up. The status of retinopathy was classified according to Fukuda's classification [10] . DR was defined as [A1 in this study. Coronary artery disease (CAD) and peripheral artery disease (PAD) were assessed and treated by cardiologists. CAD was defined as the need for percutaneous coronary intervention and/or coronary artery bypass graft surgery. PAD was defined as the need for percutaneous intervention for lower limb ischemia.
Statistical analysis
Matrix Laboratory (MATLAB) version 2015b for Windows (MathWorks, Natick, MA, USA) was used for all statistical analyses, including multivariate linear regression analyses. Variables that had a significant relationship with the logarithm of DeGFR (log DeGFR) were analyzed by multivariate linear regression analysis with forward stepwise selection of variables. All characteristics were presented as binary categorical variables; the characteristics listed in Tables 2 and 3 were used as explanatory variables. All reported P values were two-tailed, and a P value of \0.05 was considered significant.
Results
The clinical characteristics on the first visit are shown in Table 1 . The male-to-female ratio of the study population was 3:1. Systolic and diastolic BPs did not reach the recommended levels [11] . The prevalence of smoking in this study was higher than that in the general Japanese adult population, which was 34 % among men and 9 % among women (2012, Ministry of Health, Labor and Welfare of Japan). The median diabetes duration was 12 years. Diabetes prevalence among patients who had a first-degree relative with diabetes was 60 %. Half the patients had previous intermittent treatments for more than 1 year. Sixty-six percent (60/91) of the patients had received treatment for diabetes before their first visit; 22 % (20/91) had not received treatment before their first visit, despite being diagnosed with diabetes; and 11 % (11/91) of the patients were diagnosed with diabetes on their first visit and subsequently received treatment. Other comorbid conditions included hypertension (HTN, 66 %), CAD (21 %), PAD (11 %), and cerebral infarction (CI, 11 %). Before the first visit and during the follow-up, 84 % of the patients were treated with calcium channel blockers (CCBs), and 95 % were treated with renin-angiotensin system inhibitors (RASIs). Diabetes was treated with oral hypoglycemic agents in 29 % of the patients and with insulin in 70 %; lipid-lowering and antiplatelet drugs were prescribed in 61 and 41 % of the patients, respectively. Table 2 shows the CKD stage of patients on their first clinical visit. CKD was categorized as stages G1-2 (N = 40) and stage G3 (N = 51) [6] . Albuminuria was categorized into stage A1 (N = 3), stage A2 (N = 15), and stage A3 (N = 73). Most patients had DR and albuminuria on their first visit; only three patients developed DR before CKD.
Comparison of the two groups of patients based on the CKD stage is shown in Table 1 . Age, BMI, duration of diabetes, prevalence of HTN and CAD, and prescription of antiplatelet drugs were significantly higher in CKD stage G3 than in CKD stages G1-2.
Serum albumin (Alb), TBil, uric acid (UA), LDL-C, HDL-C, triglyceride (TG), and HbA1c levels as well as eGFR and ACR on the first visit are shown in Table 3 . The median eGFR of all patients was 57 mL/min/1.73 m 2 . Most patients were under poor glycemic control and had macroalbuminuria. Compared with patients with CKD stage G3, patients with CKD stages G1-2 had significantly Data indicate the number of patients eGFR estimated glomerular filtration ratio, ACR albumin to creatinine ratio lower UA and TG levels and ACR but had higher HDL-C and HbA1c levels. Figure 1 shows the comparison of the eGFR trajectories from the first visit until ESRD between CKD stages G1-2 and G3. In most patients in both groups, eGFR had already started to decline on the first visit. However, in some patients, eGFR remained stable at CKD stages G1-G2 for several years before linearly declining to the ESRD level.
To show the annual decline rate, DeGFR in each patient was calculated using the entire eGFR data in CKD stages G3-4. The overall distribution of patients categorized by DeGFR value is shown in Fig. 2a , whereas a comparison between the groups is shown in Fig. 2b . The median DeGFR (mL/min/1.73 m 2 per year) was 9.2 [interquartile range (IQR) 5.1-15] among all patients and was significantly higher in patients with CKD stages G1-2 than in The factors influencing DeGFR were investigated in all patients and also according to the CKD stage by forward stepwise selection of variables; Akaike's information criterion was used as the indicator. Log DeGFR was used as the dependent variable because DeGFR was not normally distributed (Fig. 2a) . A model using positive variables (history of CAD, initial eGFR, and HDL-C) and negative variables (age, history of CI, and Alb) was selected to predict log DeGFR in all patients (adjusted R 2 = 0.42, Table 4 ). In patients with CKD stages G1-2, male sex and diastolic BP were selected as the positive variables (adjusted R 2 = 0.37). In patients with CKD stage G3, LDL-C was selected as the positive predictor, whereas history of CI and serum TBil were the negative variables (adjusted R 2 = 0.37). Patients were further divided into two groups based on the median DeGFR as cutoff; age, history of CI, initial eGFR, and Alb levels were significantly different between these two groups (Table 5) .
Discussion
We analyzed the trajectories and rates of eGFR decline from the first clinical visit until ESRD in Japanese type 2 diabetes patients with DKD. In type 1 diabetes, it has been reported that once eGFR starts to decline, deterioration of renal function becomes abrupt and continues at an almost constant rate until ESRD is attained [5] . In our study population that comprised patients with type 2 diabetes, the eGFR trajectories from CKD stages G1-2 were similar to those reported for type 1 diabetic patients with DKD. Krolewski et al. proposed new models of diabetic nephropathy progression in type 1 diabetes: early and late renal declines [5] . In this study, the decline rates in patients with initial CKD stages G1-2 and stages G3-4 seemed to correspond with the previously reported early and late renal decline models, respectively. Therefore, it is possible that both early and late renal declines may also occur in patients with type 2 diabetes.
The distribution of DeGFR in our study population was similar to that reported for type 1 diabetes. More than 60 % of the patients in this study fulfilled the definition of rapid progressive decline of renal function in type 1 diabetes (eGFR slope [7 mL/min/year) [5] . Renal function has been reported to decline very rapidly (eGFR decline rate [50 mL/min/year) in some patients with type 1 diabetes [5] . We observed four patients with DeGFR of [30 mL/ min/1.73 m 2 per year who rapidly progressed to ESRD. These patients may have suffered from acute kidney injury or other concomitant serious renal problems. However, there may be rare cases of type 2 diabetes, as well as some cases of type 1 diabetes, in which renal function declines very rapidly despite the absence of any documented evidence of acute kidney events such as acute kidney injury. Interestingly, the distribution of DeGFR differed according to the CKD stage on the first visit (stages G1-2 vs. stage G3); this suggested that initial eGFR influences DeGFR. Multivariate linear regression analysis clearly showed initial eGFR as a positive predictor for log DeGFR. It was suggested that treatment with BP-lowering medications, including RASI, was associated with an initial fall in GFR that was most likely due to a reduction in intraglomerular pressure [12] [13] [14] . It was also previously demonstrated that a decrease in eGFR during losartan treatment is negatively correlated with long-term eGFR decline [15] . Because a b Fig. 2 Distribution of slopes of eGFR decline at CKD stages G3-4. a Overall; b according to CKD stages G1-2 (blue) and G3 (brown). eGFR estimated glomerular filtration rate, CKD chronic kidney disease, DeGFR annual eGFR decline rate most patients with low eGFR were treated with RASIs on the first visit, the lower DeGFR in these patients may be accounted for by RAS inhibition.
Among all patients, the common risk factors on the first visit for eGFR decline and progression to ESRD were age, history of CAD and CI, and Alb. Age is an established risk factor for ESRD [16] [17] [18] . Our findings suggest that an earlier onset of diabetes mellitus was associated not only with ESRD incidence but also with eGFR decline rate. The histories of CAD and CI were positive and negative predictors, respectively. Cardiovascular dysfunction reportedly leads to renal dysfunction [7] . Silent CI has been reported to be a predictor of progression of nephropathy in patients with type 2 diabetes [19] . However, a history of CI was a negative predictor for eGFR decline in the present study. We presume that this difference is due to the intake of medications for HTN, hyperlipidemia, and antiplatelets in our patients who had overt CI even before their initial visit. However, this hypothesis needs to be verified.
ACR was associated with a faster eGFR decline in patients with DKD [20] . The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated that proteinuria is the single most powerful predictor of adverse renal outcomes with respect to nephropathy progression in patients with type 2 diabetes [21] . In Japan, where ACR is generally not measured in patients with macroalbuminuria, it might be useful to evaluate Alb levels instead of ACR levels when attempting to predict DeGFR.
Unexpectedly, HDL-C was a positive predictor of log DeGFR. It was reported that a higher mean HDL-C level was associated with a lower risk of developing diabetic nephropathy in patients with type 2 diabetes [22] . It was also reported that a higher HDL-C level was not associated 
Based on multivariate linear regression analysis with stepwise forward selection of variables using log DeGFR as the dependent variable SE standard error, BP blood pressure, CAD coronary artery disease, CI cerebral infarction, eGFR estimated glomerular filtration ratio, Alb albumin, TBi1 total bilirubin, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol with a reduced mortality risk and CAD severity in patients with reduced kidney function [23] . Furthermore, patients with CKD were reported to show changes in the composition of and decreased protective function of HDL-C [24] . The vascular effects of HDL-C in patients with DKD might differ from those in normal patients. A recent experiment using HDL-C obtained from blood of children and adults with CKD (G2-3) (HDL-CKD) demonstrated that HDL (CKD) promoted endothelial superoxide production, substantially reduced nitric oxide bioavailability, and subsequently increased arterial BP in mice compared with HDL-C from healthy people [25] . We performed separate multivariate linear regression analyses for patients with CKD stages G1-2 and G3. In patients with CKD stages G1-2, male sex and diastolic BP, which are established risk factors for DKD, were selected. In patients with CKD stage G3, history of CI, LDL-C, and TBil were selected. LDL-C, a factor that commonly contributes to renal function decline [7] , was a positive predictor of log DeGFR; TBil levels were negatively correlated with log DeGFR. Bilirubin is known to be a potent endogenous antioxidant [26] ; in fact, a recent study in rodents found that bilirubin has a protective effect against diabetic nephropathy by inhibiting oxidative stress through the downregulation of renal NADPH oxidase [27] . Several cross-sectional studies in humans have shown a protective effect of bilirubin on diabetic nephropathy. Inoguchi et al. showed a lower prevalence of vascular complications, as well as reduced markers of oxidative stress and inflammation, in patients with Gilbert syndrome (congenital hyperbilirubinemia) and diabetes [28] . Low serum bilirubin levels were also associated with diabetic nephropathy progression in patients with type 2 diabetes [29, 30] . A post hoc analysis in the RENAAL trial with independent replication of the Irbesartan diabetic nephropathy trial (IDNT) indicated an independent inverse association of bilirubin with progression of nephropathy [31] . Therefore, serum TBil level could be a predictor of the rate of kidney function decline in patients with advanced DKD.
Our study had some limitations. First, this retrospective study was based on a small sample size in a single center. Larger and longer-term studies at multiple centers will be needed to draw more concrete conclusions. Second, we diagnosed DKD based on the presence of DR and laboratory data. The presence of diabetic glomerulopathy on renal biopsy was confirmed in five patients only. It is important to carry out renal biopsy on more patients for a definitive diagnosis. Third, this study had insufficient standardization of treatment regimens and glycemic and BP goals, although the therapies for glycemic control and BP control were based on guidelines [6, 8] . Also, differences in clinician competency may have affected the choice of drug regimen and targets (i.e., glycemic and BP control); unmeasured clinical and social interactions may have also influenced treatment efficacy [32] .
In conclusion, based on our analyses of the trajectories and rates of eGFR decline until ESRD in Japanese type 2 diabetic patients with DKD, early and late renal declines may occur in type 2 diabetes, as seen in type 1 diabetes. In addition to the common risk factors for ESRD, initial eGFR, HDL-C, and TBil on the first visit were identified as novel risk factors that influence renal function decline. These risk factors might differ between patients with earlystage and advanced-stage CKD.
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